Document:

Document

Effective March 27, 2019

DENTSPLY SIRONA Inc.
NON-EMPLOYEE DIRECTOR COMPENSATION POLICY
Purpose
DENTSPLY SIRONA Inc. (the “Company") believes that the granting of compensation to its members of the Board of Directors (the “Board,” and members of the Board, “Directors”) represents a powerful tool to attract, retain and reward Directors of the Company. This Director Compensation Policy (the “Policy”) is intended to formalize the Company’s policy regarding grants of equity and cash compensation to its non-employee Directors. This Policy does not apply to Directors who serve as employees of the Company; such Directors do not receive any additional compensation for their service on the Board. 
Administration
1. The Human Resources Committee of the Board shall evaluate Director compensation in accordance with its charter and may request the input of the Company’s management and an independent compensation consultant of its choosing on the status of compensation of directors. The Human Resources Committee shall review the Policy and shall make recommendations to the Board for potential amendments. 
2. The Board shall approve the Policy and shall have the authority to construe and interpret the Policy, prescribe, amend and rescind rules relating to the Policy’s administration and take any other actions necessary or desirable for the administration of the Policy. The Board may correct any defect or supply any omission or reconcile any inconsistency or ambiguity in the Policy. The decisions of the Board are final and binding on all persons. 
Annual Retainer
3. The Company shall pay to directors an annual retainer as follows: 
						
	All directors
	$85,000, payable in cash

	Non-Executive Chairman of the
Board (the “Chairman”), if any	$132,000, consisting of a cash payment of $66,000 and a grant of restricted stock units valued at $66,000

	Lead Director, if any
	$30,000 (in addition to retainer payable to all directors), payable in cash

4. One quarter of the respective annual retainers are payable in cash in advance of each calendar quarter, except as provided in Section 5.
5. The portion of the Chairman’s annual retainer that is payable restricted stock units is paid at the same time as the annual long-term incentive award described below. In the event a Chairman is appointed between meetings of stockholders, a prorated grant is automatically made in accordance with provisions of Section 13.
Committee Membership and Chair Compensation
6. The chairman of each Board committee receives annual fees as follows:
•Audit and Finance Committee Chair: $22,500
•Human Resources Committee Chair: $20,000

•Corporate Governance and Nominating Committee Chair: $15,000
•Executive Committee Chair: $20,000
Other Directors serving as members of a committee receive annual fees as follows:
•Audit and Finance Committee Member: $7,500
•Human Resources Committee Member: $5,000
•Corporate Governance and Nominating Committee Member: $5,000
•Executive Committee Member: $5,000
7. One quarter of the respective committee and committee chair fees are payable in cash in advance of each calendar quarter.
Long-Term Incentive Awards
8. On the second trading day after each annual meeting of stockholders of the Company, after any stockholder votes are taken on such date, each Director who is to continue to serve as a director is automatically granted, without further action of the Board, an award (an “Annual Award”) consisting of a grant of restricted stock units valued at $175,000.
9. The value of one restricted stock unit granted pursuant to this Policy equals the fair market value of the Company’s common stock, which is the closing stock price.
10. All Annual Awards and the portion of the Chairman’s annual retainer that is payable in restricted stock units vest one year from the date of the grant, or, if earlier, upon a director attaining the age of 75.  Annual Awards granted in the form of stock options are exercisable following the vesting for ten years from the grant date.
11. Upon vesting, the restricted stock units are payable to Directors in shares of common stock unless the Director elects to defer settlement of the restricted stock units to a future date. 
12. Directors are entitled to receive dividend equivalents on the restricted stock units in the event the Company pays a regular cash dividend on its common stock.
13. Any Director who becomes a director between annual meetings of stockholders automatically receives, without further action of the Board, a prorated award described above for the remaining term  in office, effective on the date of the next meeting of the Board following the appointment of the Director (or upon becoming a Chairman, as applicable). 
General Provisions
14. The amounts to be paid to Directors under the Policy are unfunded obligations of the Company. The Company is not required to segregate any monies or other assets from its general funds with respect to these obligations. Directors do not have any preference or security interest in any assets of the Company other than as a general unsecured creditor. Directors will be solely responsible for any tax obligations they incur as a result of the equity and cash payments received under this Policy.
15. The Board, in its sole discretion, may change and otherwise revise the terms of the cash compensation granted under this Policy, including, without limitation, the amount of cash compensation to

 be paid, on or after the date the Board or the Committee determines to make any such change or revision.
16. Each equity incentive award granted pursuant to this Policy is evidenced by an agreement in such form as the Board has authorized.
17. Neither the Policy nor any compensation paid hereunder will confer on any Director the right to continue to serve as a member of the Board or in any other capacity. Any and all rights of a Director respecting payments under this Policy may not be assigned, transferred, pledged or encumbered in any manner, other than by will or the laws of descent and distribution, and any attempt to do so is void. This Plan will remain in effect until it is revised or terminated by further action of the Board.NON-QUALIFIED
STOCK OPTION AGREEMENT

 

MARINA
BIOTECH, INC.

 

* 
*  *  *  *

 

Optionee:
_______________

 

Grant
Date: May 2, 2018

 

Per
Share Exercise Price: $0.98

 

Number
of Option Shares subject to this Option: __________

 

* 
*  *  *  *

 

THIS
NON-QUALIFIED STOCK OPTION AGREEMENT (this “Agreement”), dated as of the Grant Date specified above,
is entered into by and between Marina Biotech, Inc., a Delaware corporation (the “Company”), and the
Optionee specified above; and

 

WHEREAS,
it has been determined that it would be in the best interests of the Company to grant the non-qualified stock option provided
for herein to the Optionee;

 

NOW,
THEREFORE, in consideration of the mutual covenants and premises hereinafter set forth and for other good and valuable consideration,
the parties hereto hereby mutually covenant and agree as follows:

 

1.
Definitions.
For purposes of this Agreement, the following terms shall have the meanings set forth below:

 

1.1
“Board” shall mean
the Board of Directors of the Company, as constituted from time to time.

 

1.2
“Code” shall mean
the Internal Revenue Code of 1986, as in effect and as amended from time to time, or any successor statute thereto, together with
any rules, regulations and interpretations promulgated thereunder or with respect thereto.

 

1.3
“Committee” shall
mean the Compensation Committee of the Board, or such other committee of the Board as is established from time to time in the
sole discretion of the Board, to administer the Option, as described below in Section 7.

 

    	 	 	 

    	 	-2-	 

    

 

1.4
“Common Stock”
shall mean the Common Stock, par value $0.006 per share, of the Company or any security of the Company issued by the Company in
substitution or exchange therefor. In the event of a change in the Common Stock that is limited to a change in the designation
thereof to “Capital Stock” or other similar designation, or to a change in the par value thereof, or from par value
to no par value, without increase or decrease in the number of issues shares, the shares resulting from any such change shall
be deemed to be Common Stock.

 

1.5
“Subsidiary(ies)”
shall mean any corporation, trust (other than the Company), partnership or limited liability company in an unbroken chain of entities,
including and beginning with the Company, if each of such entities, other than the last entity in the unbroken chain, owns, directly
or indirectly, more than fifty percent (50%) of the voting shares, partnership, beneficial or membership interests in one of the
other entities in such chain.

 

2.
Grant of Option.
The Company hereby grants to the Optionee, as of the Grant Date specified above, a non-qualified stock option (this “Option”)
to acquire from the Company at the Per Share Exercise Price specified above the aggregate number of shares of the Common Stock
specified above (the “Option Shares”). This Option is not to be treated as (and is not intended to qualify
as) an incentive stock option within the meaning of Section 422 of the Code.

 

3.
No Dividends Equivalents.
The Optionee shall not be entitled to receive a cash payment in respect of the Option Shares underlying this Option on any dividend
payment date for the Common Stock.

 

4.
Exercise of this Option.

 

4.1
Unless otherwise provided in Section 4.4
below or determined by the Committee, this Option shall become exercisable immediately upon effectiveness of this Agreement.

 

4.2
This Option shall expire and shall no longer
be exercisable after the expiration of five years from the Grant Date (the “Option Period”).

 

4.3
In no event shall this Option be exercisable
for a fractional share of Common Stock.

 

5.
Method of Exercise and Payment.
This Option shall be exercised by the Optionee by delivering
to the Secretary of the Company or his designated agent on any business day (the “Exercise Date”) a
written notice, in such manner and form as may be required by the Company, specifying the number of the Option Shares the Optionee
then desires to acquire (the “Exercise Notice”). The Exercise Notice shall be accompanied by payment
of the aggregate Per Share Exercise Price (and any tax withholding pursuant to Section 9 below) for such number of the Option
Shares to be acquired upon such exercise, with payment being made in cash, by certified check, bank draft or money order payable
to the order of the Company, or by any other mechanism permitted by the Board, in its sole discretion. Payment instruments shall
be received by the Company subject to collection. The proceeds received by the Company upon exercise of the Option may be used
by the Company for general corporate purposes. Any portion of the Option that is exercised may not be exercised again. As a condition
of exercising, the Committee, in its sole discretion, may require that the Optionee become a party to a shareholders’ agreement
or enter into one or more similar agreements with respect to any equity received or to be received by the Optionee upon exercise
of the Option, with the terms of such agreement being those that the Committee considers appropriate, including, but not limited
to, transfer restrictions, Company call rights upon termination of the Optionee’s employment, and Company drag along rights.

 

    	 	 	 

    	 	-3-	 

    

 

6.
Non-transferability.
This Option, and any rights or interests therein, shall not be sold, exchanged, transferred, assigned or otherwise disposed of
in any way at any time by the Optionee (or any beneficiary(ies) of the Optionee), other than by testamentary disposition by the
Optionee or the laws of descent and distribution, or, to the extent permitted by the Board in its sole discretion, transferred
in connection with estate planning purposes. This Option shall not be pledged, encumbered or otherwise hypothecated in any way
at any time by the Optionee (or any beneficiary(ies) of the Optionee) and shall not be subject to execution, attachment or similar
legal process. Any attempt to sell, exchange, pledge, transfer, assign, encumber or otherwise dispose of or hypothecate this Option,
or the levy of any execution, attachment or similar legal process upon this Option, contrary to the terms of this Agreement shall
be null and void and without legal force or effect. Except to the extent that the Board has permitted a transfer of this Option
in connection with estate planning purposes, this Option shall be exercisable during the Optionee’s lifetime only by the
Optionee.

 

7.
Administration.

 

7.1
The Committee.
This Agreement shall be administered by the Board or the Committee, as determined by the Board in its sole discretion. In the
event that the Board determines that the Agreement shall be administered by the Committee, then the Committee may exercise all
the powers granted to the Board hereunder. Members of the Committee shall serve at the pleasure of the Board and the Committee
may at any time and from time to time remove members from, or add members to the Committee.

 

7.2
Administration and Rules.
The Board shall construe and interpret this Agreement and shall promulgate, amend and rescind any rules and regulations relating
to the implementation and administration of the Agreement. Subject to the terms and conditions of the Agreement, the Board shall
make all determinations necessary or advisable for the implementation and administration of the Agreement including, without limitation,
correcting any technical defect(s) or technical omission(s), or reconciling any technical inconsistency(ies), in this Agreement
and/or any other applicable agreement. The Board’s determinations under the Agreement and similar agreements need not be
uniform and may be made selectively, regardless of whether the individuals involved are similarly situated. Any determination,
decision or action of the Board in connection with the construction, interpretation, administration, or implementation of the
Agreement shall be final, conclusive and binding upon Optionee and any person(s) claiming under or through Optionee. The Board
may designate persons other than members of the Board or the Committee to carry out the day-to-day ministerial administration
of the Agreement under such conditions and limitations as it may prescribe.

 

    	 	 	 

    	 	-4-	 

    

 

7.3
Liability Limitation.
Neither the Board nor the Committee, nor any member of either, shall be liable for any act, omission, interpretation, construction
or determination made in good faith in connection with this Agreement, and the members of the Board and the Committee shall be
entitled to indemnification and reimbursement by the Company in respect of any claim, loss, damage or expense (including, without
limitation, attorneys’ fees) arising or resulting therefrom to the fullest extent permitted by law and/or under any directors
and officers liability insurance coverage which may be in effect from time to time.

 

8.
Changes in Capitalization and Other
Matters.

 

8.1
No Corporate Action Restriction.
The existence of the Agreement shall not limit, affect or restrict in any way the right or power of the Board or the stockholders
of the Company to make or authorize: (a) any adjustment, recapitalization, reorganization or other change in the Company’s
or any Subsidiary’s capital structure or its business; (b) any merger, consolidation or change in the ownership of the Company
or any Subsidiary; (c) any issue of bonds, debentures, capital, preferred or prior preference shares ahead of or affecting the
Company’s or any Subsidiary’s capital shares or the rights thereof; (d) any dissolution or liquidation of the Company
or any Subsidiary; (e) any sale or transfer of all or any part of the Company’s or any Subsidiary’s assets or business;
or (f) any other trust act or proceeding by the Company or any Subsidiary. Neither the Optionee nor any other person shall have
any claim against any member of the Board, the Committee, the Company or any Subsidiary, or any stockholders or agents of the
Company or any Subsidiary, as a result of any such action.

 

8.2
Changes in Capital Structure.
This Agreement and the Option granted hereunder shall be subject to adjustment or substitution, as determined by the Board in
its sole discretion, as to the number, price or kind of shares or other consideration subject to the Agreement or as otherwise
determined by the Board to be equitable: (i) in the event of changes in the outstanding shares or in the capital structure of
the Company by reason of share or extraordinary cash dividends, stock splits, reverse stock splits, recapitalization, reorganizations,
mergers, consolidations, combinations, exchanges, or other relevant changes in capitalization occurring after the date of this
Agreement; or (ii) in the event of any change in applicable laws or any change in circumstances which results in or would result
in any substantial dilution or enlargement of the rights granted to, or available for, Optionee, or which otherwise warrants equitable
adjustment because it interferes with the intended operation of the Agreement. The Company shall give the Optionee notice of an
adjustment hereunder and, upon notice, such adjustment shall be final, conclusive and binding for all purposes.

 

Notwithstanding
the above, in the event of any of the following:

 

(a)
The Company is merged or consolidated with another entity;

 

(b)
All or substantially all of the assets of the Company are acquired by another person;

 

(c)
The reorganization or liquidation of the Company; or

 

    	 	 	 

    	 	-5-	 

    

 

		(d)	The Company entering into a written agreement to undergo
an event described in clauses (a), (b) or (c) above;

 

then
the Board may, in its sole discretion, cancel the Option and this Agreement and cause the Optionee to be paid, in cash or shares
(including any shares of a successor or acquirer), or any combination thereof, the value of the Option as determined by the Board,
with such value based upon the excess of the value of a share of Common Stock over the exercise price per share.

 

9.
Miscellaneous.

 

9.1
Entire Agreement; Amendment.
This Agreement contains the entire agreement between the parties hereto with respect to the subject matter contained herein, and
supersedes all prior agreements or prior understandings, whether written or oral, between the parties relating to such subject
matter. The Board or the Committee shall have the right, in its sole discretion, to modify or amend this Agreement from time to
time in accordance with and as provided hereunder; provided, however, that, except as provided in the next sentence,
no such modification or amendment shall materially and adversely affect the rights of the Optionee under this Option without the
consent of the Optionee. The Board may amend this Agreement, without the consent of the Optionee, in any way it deems appropriate
to satisfy Code Section 409A and any regulations or other authority promulgated thereunder, including any amendment to this Agreement
to cause it not to be subject to Code Section 409A. The Company shall give written notice to the Optionee of any such modification
or amendment of this Agreement as soon as practicable after the adoption thereof. This Agreement may also be modified or amended
by a writing signed by both the Company and the Optionee.

 

9.2
Notices.
Any Exercise Notice or other notice which may be required or permitted under this Agreement shall be in writing, and shall be
delivered in person or via facsimile transmission, overnight courier service or certified mail, return receipt requested, postage
prepaid, properly addressed as follows:

 

(a)
If such notice is to the Company, to the attention of the Secretary of Marina Biotech, Inc., 17870 Castleton Street, Suite 250,
City of Industry, California 91748, or at such other address as the Company, by notice to the Optionee, shall designate in writing
from time to time.

 

(b)
If such notice is to the Optionee, at his or her address as shown on the Company’s records, or at such other address as
the Optionee, by notice to the Company, shall designate in writing from time to time.

 

9.3
Governing Law.
This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without reference to the
principles of conflict of laws thereof.

 

    	 	 	 

    	 	-6-	 

    

 

9.4
Compliance with Laws.
The issuance of this Option (and the Option Shares upon exercise of this Option) pursuant to this Agreement shall be subject to,
and shall comply with, any applicable requirements of any federal and state securities laws, rules and regulations (including,
without limitation, the provisions of the Securities Act of 1933, the Exchange Act and the respective rules and regulations promulgated
thereunder) and any other law or regulation applicable thereto. The Company shall not be obligated to issue this Option or any
of the Option Shares pursuant to this Agreement if any such issuance would violate any such requirements.

 

9.5
Binding Agreement; Assignment.
This Agreement shall inure to the benefit of, be binding upon,
and be enforceable by the Company and its successors and assigns. The Optionee shall not assign any part of this Agreement without
the prior express written consent of the Company.

 

9.6
Counterparts.
This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which
shall constitute one and the same instrument.

 

9.7
Headings.
The titles and headings of the various sections of this Agreement have been inserted for convenience of reference only and shall
not be deemed to be a part of this Agreement.

 

9.8
Further Assurances.
Each party hereto shall do and perform (or shall cause to be done and performed) all such further acts and shall execute and deliver
all such other agreements, certificates, instruments and documents as any party hereto reasonably may request in order to carry
out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated thereunder.

 

9.9
Severability.
The invalidity or unenforceability of any provisions of this Agreement in any jurisdiction shall not affect the validity, legality
or enforceability of the remainder of this Agreement in such jurisdiction or the validity, legality or enforceability of any provision
of this Agreement in any other jurisdiction, it being intended that all rights and obligations of the parties hereunder shall
be enforceable to the fullest extent permitted by law.

 

9.10
Tax Withholding.
The Company shall have the right to require payment from Optionee to cover any applicable taxes due upon any payment or settlement
under this Agreement. In addition, the Company shall have the right to deduct from any payment or settlement under this Agreement,
any federal, state, local, foreign or other taxes of any kind which the Board, in its sole discretion, deems necessary to be withheld
to comply with the Code and/or any other applicable law, rule or regulation.

 

9.11
No Right to Continued Relationship
with the Company. Neither this Agreement nor the Option
granted hereunder shall confer upon Optionee any right to continued employment, Board membership or consulting relationship with
the Company or any Subsidiary, as the case may be, nor shall it interfere in any way with the right, if any, of the Company or
any Subsidiary to terminate the employment, directorship or consulting relationship of any employee, director or consultant at
any time for any reason, even if such termination adversely affects the Option.

 

    	 	 	 

    	 	-7-	 

    

 

9.12
Listing, Registration and Other Legal
Compliance. No Common Stock shall be required to be issued
or granted under this Agreement unless legal counsel for the Company shall be satisfied that such issuance will be in compliance
with all applicable securities laws and regulations and any other applicable laws or regulations. The Board may require, as a
condition of any payment or share issuance, that certain agreements, undertakings, representations, certificates, and/or information,
as the Board may deem necessary or advisable, be executed or provided to the Company to assure compliance with all such applicable
laws or regulations. Certificates for Common Stock delivered under this Agreement shall bear appropriate legends and may be subject
to such transfer orders and such other restrictions as the Board may deem advisable under the rules, regulations, or other requirements
of the Securities and Exchange Commission, any stock exchange upon which the Common Stock is listed, and any applicable securities
law. In addition, if, at any time specified herein for: (a) the making of any determination; (b) the issuance or other distribution
of Common Stock; or (c) the payment of amounts to or through the Optionee, any law, rule, regulation or other requirement of any
governmental authority or agency shall require either the Company, any Subsidiary or Optionee (or any estate, designated beneficiary
or other legal representative thereof) to take any action in connection with any such determination, any such shares to be issued
or distributed, any such payment, or the making of any such determination, as the case may be, shall be deferred until such required
action is taken.

 

9.13
Designation of Beneficiary.
Optionee may designate a beneficiary or beneficiaries to exercise the Option or to receive any payment which under the terms of
this Agreement may become exercisable or payable on or after the Optionee’s death. At any time, and from time to time, any
such designation may be changed or cancelled by Optionee without the consent of any such beneficiary. Any such designation, change
or cancellation must be on a form provided for that purpose by the Board and shall not be effective until received by the Board.
If no beneficiary has been designated by a deceased Optionee, or if the designated beneficiaries have predeceased the Optionee,
the beneficiary shall be the Optionee’s estate. If the Optionee designates more than one beneficiary, any payments under
this Agreement to such beneficiaries shall be made in equal shares unless the Optionee has expressly designated otherwise, in
which case the payments shall be made in the shares designated by the Optionee.

 

9.14
Code Section 409A. This
Agreement is intended to comply with the requirements of Code Section 409A and any regulations or other authority promulgated
thereunder. Notwithstanding any provision of this Agreement to the contrary, the Board and the Committee reserve the right (without
the consent of the Optionee and without any obligation to do so or to indemnify the Optionee or the beneficiaries of the Optionee
for any failure to do so) to amend this Agreement as and when necessary or desirable to conform to or otherwise properly reflect
any guidance issued under Code Section 409A after the date hereof without violating Code Section 409A. In the event that any payment
or benefit made hereunder would constitute payments or benefits pursuant to a non-qualified deferred compensation plan within
the meaning of Code Section 409A and, at the time of Optionee’s “separation from service”, Optionee is a “specified
employee” within the meaning of Code Section 409A, then any such payments or benefits shall be delayed until the six-month
anniversary of the date of Optionee’s “separation from service”, if such delay is necessary in order to prevent
any accelerated or additional tax under Code Section 409A. Each payment made under this Agreement shall be designated as a “separate
payment” within the meaning of Code Section 409A.

 

[remainder
of page intentionally left blank; signature page follows]

 

    	 	 	 

    	 	-8-	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer, and the Optionee has
hereunto set his hand, all as of the Grant Date specified above.

 

	 	MARINA
    BIOTECH, INC.
	 	 
	 	By:	 
	 	Name:	 
	 	Title:
	      
	 	 
	 	 
	 	Optionee:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}]]